A threshold LC-MS/MS method for 92 analytes in oral fluid collected with the Quantisal® device.
Chromatography, Liquid
Driving Under the Influence
Forensic Toxicology
/ instrumentation
Humans
Illicit Drugs
/ analysis
Pharmaceutical Preparations
/ analysis
Predictive Value of Tests
Reproducibility of Results
Saliva
/ chemistry
Substance Abuse Detection
/ instrumentation
Tandem Mass Spectrometry
Liquid chromatography tandem mass spectrometry
Oral fluid
Qualitative decision point methods
Quantisal
Roadside survey
Saliva
Journal
Forensic science international
ISSN: 1872-6283
Titre abrégé: Forensic Sci Int
Pays: Ireland
ID NLM: 7902034
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
30
06
2020
revised:
07
09
2020
accepted:
08
09
2020
pubmed:
10
10
2020
medline:
13
5
2021
entrez:
9
10
2020
Statut:
ppublish
Résumé
A study of impaired driving rates in the province of Québec is currently planned following the legalization of recreational cannabis in Canada. Oral fluid (OF) samples are to be collected with a Quantisal® device and sent to the laboratory for analysis. In order to prepare for this project, a qualitative decision point analysis method monitoring for the presence of 97 drugs and metabolites in OF was developed and validated. This high throughput method uses incubation with a precipitation solvent (acetone:acetonitrile 30:70 v:v) to boost drug recovery from the collecting device and improve stability of benzodiazepines (e.g., α-hydroxyalprazolam, clonazepam, 7-aminoclonazepam, flunitrazepam, 7-aminoflunitrazepam, N-desmethylflunitrazepam, nitrazepam). The Quantisal® device has polyglycol in its stabilizing buffer, but timed use of the mass spectrometer waste valve proved sufficient to avoid the glycol interferences for nearly all analytes. Interferences from OF matrices and 140 potentially interfering compounds, carryover, ion ratios, stability, recovery, reproducibility, robustness, false positive rate, false negative rate, selectivity, sensitivity and reliability rates were tested in the validation process. Five of the targeted analytes (olanzapine, oxazepam, 7-aminoclonazepam, flunitrazepam and nitrazepam) did not meet the set validation criteria but will be monitored for identification purposes (no comparison to a cut-off level). Blind internal proficiency testing was performed, where six OF samples were tested and analytes were classified as "negative", "likely positive" or "positive" with success. The final validated OF qualitative decision point method covers 92 analytes, and the presence of 5 additional analytes is screened in this high throughput analysis.
Identifiants
pubmed: 33035929
pii: S0379-0738(20)30368-6
doi: 10.1016/j.forsciint.2020.110506
pii:
doi:
Substances chimiques
Illicit Drugs
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
110506Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors report no declarations of interest.